Troy

Follicular lymphoma (FL) is the second most common B-cell cancer and the most frequent cancer of lymphocytes, but it is incurable with standard treatments and often returns. This research is a Phase 3 trial evaluating the safety and effectiveness of the investigational drug epcoritamab combined with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in adults who have not been treated for FL before. The study aims to assess adverse events and changes in disease activity among about 1095 participants worldwide. Participants are assigned to one of five treatment groups receiving different therapies. Treatments include R2 alone or combined with subcutaneous epcoritamab injections. Some may receive chemoimmunotherapy options chosen by investigators, including R-CHOP, G-CHOP, R-Benda, or G-Benda, involving various intravenous infusions and oral tablets. Most treatment arms last 120 weeks, except one lasting 24 weeks. The study treatments involve intravenous infusions, oral capsules or tablets, and subcutaneous injections. During the study, participants regularly visit hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will track responses such as complete response rates at 30 months and progression-free survival up to 10 years. The study also monitors safety and tolerability throughout. Participants’ treatment adherence and disease status will be carefully observed over the study period.

Researchers are evaluating the performance, safety, and effectiveness of the GORE4 VIABAHN4 FORTEGRA Venous Stent for treating symptomatic iliofemoral venous obstruction. This is a prospective, non-randomized, multicenter, single-arm clinical study involving up to 30 clinical sites across the U.S. The study aims to enroll 165 subjects who will receive the stent to help improve blood flow in affected veins. Participants will be treated with the GORE4 VIAFORT Vascular Stent, targeting unilateral symptomatic iliofemoral venous obstruction. The stent is implanted during a procedure designed to open blocked or narrowed veins. The study includes patients with non-malignant venous obstruction meeting specific clinical and anatomical criteria, and the procedure involves use of imaging to guide stent placement. Only one stent type is used, and treated subjects are limited per site. After treatment, participants will be followed closely starting from hospital discharge, with follow-up visits scheduled at 1, 6, 12, 24, 36, 48, and 60 months to monitor safety and device performance. Researchers will assess safety events such as stent embolization and evaluate effectiveness by measuring vein openness (primary patency) over 12 months. Additional monitoring includes clinical assessments and imaging as needed to track outcomes and ensure participant safety throughout the study duration.